Overview

Drug Combination on Exercise Performance at High Altitude

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Montana
Treatments:
Ambrisentan
Theophylline